Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share

Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.72), versus ($1.56) reported last year. Revenue for the quarter came in at $14.07 million, versus $6.87 million reported last year.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Customers Bancorp (CUBI) Tops Q1 EPS by 3c
• Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short